natgillin/translations-raw huggingface dataset:
You will only be given Zevalin by an experienced professional and it will only be handled by properly qualified staff in hospital.
Zevalin boste dobili le od izkušenega strokovnjaka, z njim pa lahko rokuje le ustrezno usposobljeno osebje v bolnišnici.
Before you are given Zevalin itself, you are given another medicine – called rituximab – to improve the effect of Zevalin.
Preden boste dobili sam Zevalin, vam bodo dali drugo zdravilo, ki se imenuje rituksimab – za izboljšanje učinka Zevalina.
The first two infusions of your treatment are actually rituximab.
Prvi dve infuziji v vašem zdravljenju bosta pravzaprav vsebovali rituksimab.
On your first visit (day 1) you will be given o One rituximab infusion
V razmaku enega tedna boste bolnišnico obiskali dvakrat. ob vašem prvem obisku (dan 1) boste prejeli o eno infuzijo rituksimaba
On your second visit (day 7, 8, or 9) you will be given o One rituximab infusion o One Zevalin infusion straight afterwards.
ob vašem drugem obisku (dan 7, 8 ali 9) boste prejeli o eno infuzijo rituksimaba o eno infuzijo Zevalina takoj za tem.
You will be given a total of 3 infusions.
Skupaj boste prejeli 3 infuzije.
That will be the end of the treatment.
S tem bo zdravljenje končano.
An infusion means that the medicine is given by a drip into a vein.
Infuzija pomeni, da dobite zdravilo po cevki, napeljani iz infuzijske steklenice v žilo.
Zevalin infusions usually take about 10 minutes.
Infuzije Zevalina trajajo običajno okoli 10 minut.
Rituximab infusions can take an hour or two.
Infuzije rituksimaba lahko trajajo uro ali dve.
The doctor will calculate your individual dose.
Koliko Zevalina prejmete Zdravnik bo izračunal vaš osebni odmerek.
This depends on your body weight and the number of your blood platelets.
Ta je odvisen od vaše telesne mase in števila krvnih ploščic – trombocitov.
The amount of radiation that your body will be exposed to during a course of Zevalin is smaller than it would be in radiotherapy.
Po prejemu Zevalina Količina sevanja, ki mu bo izpostavljeno vaše telo med terapijo z Zevalinom, je manjša kot bi bila tista pri radioterapiji.
With this type of radioactivity, there is no direct effect of radiation outside the body.
Pri tej vrsti radioaktivnosti ni neposrednega učinka sevanja na telo od zunaj.
You are not exposing other people to radiation.
Zaradi vas drugi ljudje niso izpostavljeni sevanju.
A small part of the radioactivity will leave your body through your urine.
Majhen del radioaktivnosti se bo iz vašega telesa izločil preko urina.
The remainder will decay within the body, leaving no radioactive remains.
Ostala aktivnost bo razpadla znotraj vašega telesa brez sledu radioaktivnih ostankov.
There is one simple precaution because of the radioactivity:
Je le en preprost previdnostni ukrep, ki ga morate zaradi radioaktivnosti upoštevati:
Wash your hands especially thoroughly after urinating for a week after the Zevalin infusion.
Še en teden po infuziji Zevalina si posebej skrbno umijte roke po uriniranju.
Your doctor will be taking small samples of blood at regular intervals in order to monitor blood-platelet and white-blood-cell counts.
Vaš zdravnik vam bo v rednih časovnih intervalih jemal majhne vzorce krvi za spremljanje števila trombocitov in belih krvnih celic.
These tend to show shortages around day 60 after start of treatment.
Te začnejo kazati tendenco upadanja okrog 60. dne po začetku zdravljenja.
In connection with this, your physician will ensure that all measures are taken in case of infectious events.
S tem v zvezi bo vaš zdravnik poskrbel, da bodo podvzeti vsi potrebni ukrepi v primeru pojava infekcij.
If you have received more Zevalin than you should have:
Če ste prejeli večji odmerek zdravila Zevalin kot bi smeli:
In case you have had too much Zevalin administered, your doctor will stop the administration of Zevalin and treat your symptoms (e. g. with growth factors).
V primeru, da ste prejeli prevelik odmerek zdravila Zevalin, vam bo vaš zdravnik ustavil aplikacijo zdravila Zevalin in zdravil simptome (t. j. z rastnim faktorjem).
In such a case you also may receive stem cells to manage the toxic effects on your blood cells.
V takih primerih lahko dobite tudi matične celice za obvladovanje toksičnega učinka na vaše krvne celice.
In case you may have received only the radioactive substance yttrium, your doctor will treat you as described in the product information of yttrium-90.
Če ste dobili le radioaktivni itrij, vas bo vaš zdravnik zdravil kot je opisano v navodilu za uporabo za itrij- 90.
Because many side effects resemble the effects of the illness, it is not always clear if a reaction seen in clinical trials was due to Zevalin or not.
Ker so mnogi neželeni učinki podobni tistim, ki jih povzroča sama bolezen, ni vedno jasno, če je bil učinek, ki so ga opazili v kliničnem preskušanju, posledica Zevalina ali ne.
If you are worried by any of these side effects, ask your doctor for advice.
32 če ste zaskrbljeni zaradi katerega koli neželenega učinka, vprašajte za nasvet svojega zdravnika.
For a few side effects even death has been reported either in clinical trials or in post marketing experience.
V kliničnih preskušanjih ali pri postmarketinškem spremljanju so poročali celo o nekaj neželenih učinkih s smrtnim izidom.
These side effects are marked with an asterisk (*).
Ti neželeni učinki so označeni z zvezdico (*).
You should tell your doctor immediately, if you notice any of the symptoms of these side effects as described below.
Takoj obvestite zdravnika, če opazite katere koli simptome spodaj opisanih neželenih učinkov.
► Tell your doctor immediately:
► Takoj obvestite svojega zdravnika:
if you notice an infection (e.g. fever, chills), symptoms of blood poisoning (e.g. fever and chills, changes in mental status, rapid breathing, increased heart rate, decreased urine output, low blood pressure, shock, problems with bleeding or clotting), or breathing difficulties.
• če opazite okužbo (npr. vročino, mrzlico), simptome zastrupitve krvi (npr. vročino in mrzlico, spremembe duševnega stanja, hitro dihanje, pospešen srčni utrip, zmanjšano izločanje urina, nizek krvni tlak, šok, težave s krvavitvijo ali strjevanjem krvi) ali težave z dihanjem
if you notice any unusual bruising, more bleeding then usual after injury, fever, or if you feel unusually tired or breathless.
• če opazite kakršne koli nenavadne podplutbe, več krvavitev, kot je navadno po poškodbi, vročino ali če se počutite nenavadno utrujeni ali ste brez sape.
In a small percentage of cancer patients participating in certain Zevalin studies, other types of cancer have been reported that relate to the blood: myelodysplastic syndrome or acute myeloid leukaemia (AML), which can even lead to death.
Pri majhnem odstotku rakavih bolnikov, ki so sodelovali v nekaterih študijah z zdravilom Zevalin, poročajo o pojavu drugih vrst raka, ki prizadene krvotvorne organe: mielodisplazija ali akutna mieloična levkemija (AML) *, ki lahko povzročijo celo smrt.
The risk of these secondary cancers occurring after therapy with alkylating agents is already well- known to doctors.
Tveganje teh sekundarnih rakavih obolenj, ki se pojavijo po zdravljenju z alkilirajočimi citostatiki, je zdravnikom dobro poznano.
However, as previous treatment with alkylating agents is widespread prior to Zevalin treatment, one does not know the exact role of Zevalin when these cancers occur after treatment with Zevalin, since radiation may potentially also cause these cancers.
Ker pa je predhodno zdravljenje z alkilirajočimi citostatiki pred zdravljenjem z zdravilom Zevalin pogosto, natančna vloga zdravila Zevalin ob pojavu teh rakov po zdravljenju z zdravilom Zevalin ni znana, saj lahko tudi sevanje povzroči te rake.
Your doctor will carefully balance the potential risks with Zevalin against the expected benefits before treating your disease with Zevalin.
Zdravnik bo skrbno pretehtal morebitna tveganja z zdravilom Zevalin in pričakovane koristi, preden bo začel vašo bolezen zdraviti z zdravilom Zevalin.
Below we list possible side effects by the parts of the body they affect and by how common they are.
Spodaj navajamo seznam možnih neželenih učinkov glede na del telesa, ki ga prizadenejo in po pogostnosti pojavljanja.
• Very common means 10 or more in every 100 patients are likely to get these:
Zelo pogosto pomeni, da bo verjetno 10 ali več na vsakih 100 bolnikov imelo te učinke:
- bruising, low numbers of platelets, red or white blood cells*,
- podplutbe, nizko število trombocitov ter rdečih in belih krvničk *
- feeling sick (nausea),
- občutek slabosti (nausea)
- weakness, fever, chills (rigor).
- oslabelost, vročina, mrzlica (rigor)
• Common means between 1 and 10 in every 100 patients are likely to get these.
Pogosto pomeni da bo verjetno 1 do 10 na vsakih 100 bolnikov imelo te učinke.
- -infection*, blood poisoning*, infection in the lungs which can lead to breathing difficulties
- okužba *; zastrupitev krvi *; okužbe pljuč, ki lahko pripelje do težav z dihanjem *, okužbe sečil,
(pneumonia)*, urinary tract infection, which can cause pain when passing urine, fungal infections in the mouth such as oral thrush,
ki lahko povzročijo bolečine pri uriniranju, glivične okužbe v ustih, kot je oralna kandidoza.
- tumor pain,, myelodysplastic syndrome / acute myeloid leukaemia (see below)*,
- bolečina zaradi tumorja, mielodsiplastični sindrom/ akutna mieloblastna levkemija (glej
- white blood-cell depletion leading up to fever (febrile neutropenia), decreased levels of all blood
spodaj) *. zmanjšano število belih krvnih celic, ki povzroči zvišano telesno temperaturo (febrilna
cells possibly leading to tiredness, frequent infections, bleeding and fever (pancytopenia)*; lower number of lymphocytes (lymphocytopenia),
nevtropenija); zmanjšane vrednosti vseh krvnih celic, ki lahko privedejo do stanja utrujenosti, pogostih okužb, krvavitev in temperature (pancitopenija) *; zmanjšano število limfocitov (limfocitopenija).
- hypersensitivity reactions,
- preobčutljivostne reakcije
- severe loss of appetite leading to weight loss (anorexia),
huda izguba apetita, ki privede do hujšanja (anoreksija).
- feeling anxious, trouble sleeping,
- občutek anksioznosti, težave s spanjem.
- dizziness, headache,
vrtoglavica; glavobol.
- bleeding due to lower platelet count*,
- krvavitev zaradi zmajšanega števila trombocitov *
- cough, runny nose,
- kašljanje; nahod
- being sick (vomiting), stomach pain, diarrhea, indigestion, throat irritation, constipation,
- slabost (bruhanje), bolečine v želodcu, driska, prebavne motnje, vneto grlo, zaprtost
- rash, itching.
- srbenje; izpuščaj
- joint pain, aching muscles, back pain, neck pain,
- bolečine v sklepih, mišične bolečine, bolečine v hrbtu, bolečine v vratu
- pain, flu-like symptoms, generally feeling unwell, swelling caused by build-up of fluid in the arms
- bolečina, gripi podobni simptomi, splošno slabo počutje, oteklost rok, nog in drugih tkiv zaradi
and legs and other tissues, increased sweating.
33 zastoja tekočine, povečano potenje.
• Uncommon means between 1 and 10 in every 1,000 patients are likely to get these.
Občasno pomeni, da bo verjetno 1 do 10 na vsakih 1000 bolnikov imelo te učinke:
- f ast heart rate.
- pospešen srčni utrip
• Rare means between 1 and 10 in every 10,000 patients are likely to get these.
Redko pomeni, da bo verjetno 1 do 10 na vsakih 10. 000 bolnikov imelo te učinke:
- a certain benign tumor in the brain (meningioma),
- benigni možganski tumor (meningiom)
- bleeding in the head due to lower platelet count*.
- krvavitve v glavi zaradi zmanjšanega števila trombocitov *.
In patients where Zevalin is used following remission induction therapy, infections were observed more frequently than described above (very common).
Pri bolnikih, pri katerih je zdravljenje z zdravilom Zevalin sledilo indukcijskemu zdravljenju, so se okužbe pojavljale pogosteje kot je opisano zgoraj (zelo pogosto).
In addition, the following side effects were observed in these patients:
Poleg tega so pri teh bolnikih opazili naslednje neželene učinke: • Zelo pogosti
• Very common:
utrujenost
- red spots under the skin (petechia)
rdeče pike pod kožo (petehije)
• Common:
• Pogosti
- high blood pressure
visok krvni tlak
- low blood pressure
nizek krvni tlak
- suppression of menstrual periods
izostanek menstruacije
Spontaneous reporting from post-marketing:
Spontana poročila iz postmarketinških izkušenj:
Skin and subcutaneous system
Koža in podkožje
Reaction of the skin and/or mucous membranes with fatal outcome has been reported (Stevens- Johnson Syndrome).
Redko: poročajo o reakcijah kože in/ ali sluznic, ki so se končale s smrtnim izidom (Stevens- Johnson sindrom).
A few cases have been reported where Zevalin leaked from the vein to the surrounding tissue, which then inflamed (infusion site dermatitis) and scars develop (infusion site desquamation) of the skin at the infusion site.
Poročali so o nekaj primerih, ko je zdravilo Zevalin uhajalo iz vene v okolno tkivo ter povzročilo vnetje (dermatitis na mestu aplikacije) in brazgotinjenje (deskvamacija na mesui infundiranja) na mestu infundiranja.
Radiation due to Zevalin might cause damage to tissue around tumors of the lymph system and might cause complications due to swelling of such tumors of the lymph system.
Ionizirajoče sevanje zaradi zdravila Zevalin lahko povzroči poškodbo tkiva okoli tumorja limfnega sistema in zaplete zaradi otekanja tumorjev.
How to store Zevalin
SHRANJEVANJE ZDRAVILA ZEVALIN
35 Keep out of the reach and sight of children.
Zdravilo shranjujte nedosegljivo otrokom!
Store in a refrigerator (2°C - 8°C) Do not freeze.
Ne zamrzujte.
After radiolabeling:
34 Po označevanju z radioizotopom:
Store at 2°C - 8°C and protect from light.
Shranjujte pri temperaturi med 2 °C in 8 °C in zaščiteno pred svetlobo.
Storage should be in accordance with national regulations for radioactive materials.
Shranjujte v skladu z nacionalnimi predpisi o radioaktivnih snoveh.
• The active substance is ibritumomab tiuxetan (3.2 mg/ 2 ml).
• Zdravilna učinkovina je ibritumomab tiuksetan (3, 2 mg/ 2 ml).
- in the ibritumomab tiuxetan vial: sodium chloride, water for injection
• Pomožne snovi so: natrijev klorid; natrijev acetat; natrijev hidroksid, raztopina humanega albumina, dinatrijev fosfat dodekahidrat; kalijev dihidrogen fosfat, kalijev klorid; (razredčena) klorovodikova kislina; pentetična kislina, voda za injekcije.
- in the sodium acetate vial: sodium acetate, water for injection
Izgled zdravila Zevalin in vsebina pakiranja:
- in the formulation buffer vial: human albumin solution, sodium chloride, disodium phosphate
Zevalin je komplet za pripravo radiofarmaka za infundiranje.
What Zevalin looks like and contents of the pack:
Bistra, brezbarvna raztopina.
- One ibritumomab tiuxetan vial
- viala z ibritumomab tiuksetanom: natrijev klorid, voda za injekcije
- One sodium acetate vial
- viala z natrijevim acetatom: natrijev acetat, voda za injekcije
- One formulation buffer vial
- viala s pufrom za pripravo formulacije: raztopina humanega albumina, natrijev klorid, natrijev
- One empty reaction vial
hidrogenfosfat dodekahidrat, natrijev hidroksid, kalijev dihidrogen fosfat, kalijev klorid, pentetična kislina, klorovodikova kislina, razredčena, voda za injekcije
France Ireland Ísland Italia Κύπρος (Kypros) Latvija Lietuva
Química Farmacéutica Bayer S. L.
Invented name
Lastniško ime zdravila
blister (PVC/ alu)
Pretisni omot (PVC/ alu)
1 bottle + 1 dosing syringe + 1 adaptor
1 plastenka + 1 odmerna brizga + 1 adapter
Ziagen is a medicine containing the active substance abacavir.
Ziagen je zdravilo, ki vsebuje zdravilno učinkovino abakavir.
It is available as yellow capsule-shaped tablets (300 mg) and as an oral solution (20 mg/ ml).
Na voljo je v rumenih tabletah (300 mg), ki imajo obliko kapsule, in v obliki raztopine za peroralno uporabo (20 mg/ ml).
Ziagen is an antiviral medicine.
Zdravilo Ziagen je protivirusno zdravilo.
It is used in combination with other antiviral medicines to treat adults and children who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Uporablja se v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje odraslih in otrok, ki so okuženi z virusom humane imunske pomanjkljivosti (HIV), to je virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
Treatment with Ziagen should be prescribed by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Ziagen lahko predpiše le zdravnik, ki ima izkušnje z zdravljenjem okužbe s HIV.
The recommended dose of Ziagen for patients over 12 years of age is 600 mg daily, either as 600 mg once a day or 300 mg twice a day.
Priporočeni odmerek zdravila Ziagen pri bolnikih, starejših od 12 let, je 600 mg dnevno, bodisi enkrat dnevno 600 mg ali dvakrat dnevno po 300 mg.
In children aged below 12 years, the dose depends on body weight.
Pri otrocih, mlajših od 12 let, je višina odmerka odvisna od njihove telesne mase.
Children taking Ziagen tablets should be closely monitored for side effects.
Otroke, ki jemljejo tablete Ziagen, je treba skrbno nadzorovati glede pojava neželenih učinkov.
Information on the use of Ziagen in children aged below three months is very limited.
Podatki o uporabi zdravila Ziagen pri otrocih, starih manj kot tri mesece, so zelo skopi.
Ziagen can be taken with or without food.
Zdravilo Ziagen lahko jemljemo s hrano ali brez nje.
Ziagen tablets should ideally be swallowed without crushing.
Najbolje je, da tableto pogoltnete celo, ne da bi jo poprej zdrobili.
Before starting treatment with Ziagen, all patients should have a test to find out if they have a specific gene called ‘ HLA-B (type 5701 )’.
Pri vsakem bolniku je treba pred začetkom zdravljenja z zdravilom Ziagen izvesti test, s katerim zdravnik ugotovi, ali ima bolnik posebni gen, imenovan HLA- B (tip 5701).
Patients with this gene have an increased risk of having an allergic reaction to abacavir, so they should only take Ziagen if there are no other treatment options.
Bolniki s tem genom so izpostavljeni višjemu tveganju za pojav alergične reakcije na abakavir, tako da lahko zdravilo Ziagen jemljejo samo, če zanje ne obstaja nobena druga možnost zdravljenja.
Patients who take Ziagen must be given the special alert card that summarises the key safety information about the medicine.
Bolnikom, ki jemljejo zdravilo Ziagen, je treba dati posebno opozorilno kartico, ki povzema najpomembnejše varnostne informacije o zdravilu.
Ziagen does
Ta preprečuje delovanje reverzne transkriptaze, encima, ki ga proizvaja virus HIV in ki omogoča okužbo celic in tvorbo novih virusov.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Z blokiranjem tega encima zdravilo Ziagen, ki se 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Reproduction is authorised provided the source is acknowledged. jemlje skupaj z drugimi protivirusnimi zdravili, zmanjša količino HIV v krvi in jo ohranja na nizki ravni.
Ziagen has been studied in six main studies including 1,843 HIV-infected adults.
Zdravilo Ziagen so raziskovali v šestih glavnih študijah, v katere je bilo vključenih 1843 odraslih bolnikov, okuženih s HIV.
Ziagen was taken alone, or added to the combination of lamivudine and zidovudine (other antiviral medicines) or the patients’ existing HIV treatment.
Zdravilo Ziagen so bolniki jemali kot samostojno zdravilo ali pa je bilo dodano kombinaciji lamivudina in zidovudina (drugima protivirusnima zdraviloma) ali k bolnikovemu obstoječemu zdravljenju okužbe s HIV.
Ziagen has also been studied in three studies including 489 HIV-infected children aged between three months and 18 years.
Zdravilo Ziagen so preučevali tudi v treh študijah, v katerih je sodelovalo 489 s HIV okuženih otrok, starih tri mesece do 18 let.
Ziagen’ s effects were compared with other antiviral medicines, placebo (a dummy treatment) or no treatment.
Učinke zdravila Ziagen so primerjali z učinki drugih protivirusnih zdravil, placebom (zdravilom brez zdravilne učinkovine) ali pa nobenim drugim zdravilom.
The main measures of effectiveness were the effect of Ziagen on the levels of HIV in the blood (viral load) and the number of CD4 T-cells in the blood (CD4 cell count).
Glavni merili učinkovitosti sta bila učinek zdravila Ziagen na ravni HIV v krvi (virusno breme) in število CD4 T- celic v krvi (število CD4 celic).
In all studies, Ziagen caused a decrease in viral loads, particularly when taken with other antiviral medicines.
V vseh študijah je zdravilo Ziagen privedlo do zmanjšanja virusnega bremena, še zlasti kadar so ga bolniki jemali skupaj z drugimi protivirusnimi zdravili.
It was more effective than placebo, and as effective as other antiviral medicines in reducing viral loads.
Pri zmanjševanju virusnega bremena je bilo učinkovitejše od placeba in enako učinkovito kot druga protivirusna zdravila.
Patients receiving Ziagen also had increases in their CD4 cell counts.
Pri bolnikih, ki so prejemali zdravilo Ziagen, se je povečalo tudi število CD4 celic.
After 16 weeks of treatment, 77% of the adults taking Ziagen with lamivudine and zidovudine had viral loads below 400 copies/ ml (67 out of 87), compared with 38% of the adults taking lamivudine and zidovudine alone (33 out of 86).
Po 16 tednih zdravljenja je 77% odraslih bolnikov, ki so jemali zdravilo Ziagen v kombinaciji z lamivudinom in zidovudinom, imelo virusno breme pod 400 kopijami/ ml (67 od 87 bolnikov), v primerjavi z 38% odraslih bolnikov, ki so jemali samo lamivudin in zidovudin (33 od 86 bolnikov).
Ziagen was of similar effectiveness to indinavir, with around two thirds of the patients having viral loads below 400 copies/ ml after 16 weeks.
Zdravilo Ziagen je bilo podobno učinkovito kot indinavir, pri čemer sta po 16 tednih zdravljenja približno dve tretjini bolnikov imeli virusno breme manj kot 400 kopij/ ml.
Once- and twice-daily Ziagen had similar effects on viral load, with around two thirds of patients having viral loads below 50 copies/ ml after 48 weeks.
Zdravilo Ziagen, ki so ga dajali enkrat ali dvakrat dnevno, je imelo podobne učinke na virusno breme, pri čemer je bilo to po 48 tednih zdravljenja pri približno dveh tretjinah bolnikov manjše od 50 kopij/ ml.
The studies in children showed that Ziagen, in combination with other antiviral medicines, reduced viral loads to a similar extent to other combinations after 24 weeks.
Študije pri otrocih so pokazale, da je zdravilo Ziagen v kombinaciji z drugimi protivirusnimi zdravili po 24 tednih zmanjšalo virusno breme v približno enakem obsegu kot druge kombinacije.
The most common side effects when taking Ziagen (seen in between 1 and 10 patients in 100) are anorexia (loss of appetite), headache, nausea (feeling sick), vomiting, diarrhoea, rash, fever, lethargy (lack of energy) and fatigue (tiredness).
Najpogostejši neželeni učinki, ki so jih opazili pri jemanju zdravila Ziagen (opaženi pri 1 do 10 bolnikih izmed 100), so anoreksija (izguba teka), glavobol, navzeja (občutek slabosti), bruhanje, driska, izpuščaji, povišana telesna temperatura, letargija (pomanjkanje energije) in utrujenost.
For the full list of all side effects reported with Ziagen, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Ziagen, glejte navodilo za uporabo.
Hypersensitivity reactions (allergic reactions) occur in about 5% of patients taking Ziagen, usually within the first six weeks of treatment.
Preobčutljivostne (alergijske) reakcije se pojavijo pri približno 5% bolnikov, ki jemljejo zdravilo Ziagen, običajno v prvih šestih tednih zdravljenja.
Some of these cases can be fatal.
Nekateri izmed teh primerov so lahko smrtni.
The risk of hypersensitivity is higher in patients who have the HLA-B (type 5701) gene.
Tveganje za pojav preobčutljivosti je večje pri bolnikih, ki imajo gen HLA- B (tip 5701).